After finishing at $0.75 in the prior trading day, Atara Biotherapeutics Inc (NASDAQ: ATRA) closed at $0.69, down -7.87%. In other words, the price has decreased by -$0.0591 from its previous closing price. On the day, 2559209 shares were traded.
Ratios:
Our goal is to gain a better understanding of ATRA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on November 09, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $31 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 16 when Touchon Pascal sold 20,409 shares for $0.39 per share. The transaction valued at 7,939 led to the insider holds 655,496 shares of the business.
Joshi Manher sold 12,287 shares of ATRA for $4,780 on Nov 16. The EVP, Chief Medical Officer now owns 171,284 shares after completing the transaction at $0.39 per share. On Nov 16, another insider, Hyllengren Eric J, who serves as the SVP, CFO of the company, sold 11,958 shares for $0.39 each. As a result, the insider received 4,652 and left with 205,998 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATRA now has a Market Capitalization of 71.12M and an Enterprise Value of 30.52M. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.68. Its current Enterprise Value per Revenue stands at 6.72 whereas that against EBITDA is -0.09.
Stock Price History:
Over the past 52 weeks, ATRA has reached a high of $3.61, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is 0.6954, while the 200-Day Moving Average is calculated to be 1.2940.
Shares Statistics:
The stock has traded on average 3.60M shares per day over the past 3-months and 2.12M shares per day over the last 10 days, according to various share statistics. A total of 129.19M shares are outstanding, with a floating share count of 117.42M. Insiders hold about 9.11% of the company’s shares, while institutions hold 51.42% stake in the company. Shares short for ATRA as of Feb 15, 2024 were 10.87M with a Short Ratio of 3.02, compared to 7.33M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.67% and a Short% of Float of 10.94%.
Earnings Estimates
Its stock is currently analyzed by 5 different market analysts. On average, analysts expect EPS of -$0.48 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.62, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.26 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$2.37 and -$2.67 for the fiscal current year, implying an average EPS of -$2.54. EPS for the following year is -$1.48, with 5 analysts recommending between -$0.5 and -$2.5.
Revenue Estimates
6 analysts predict $11.55M in revenue for the current quarter. It ranges from a high estimate of $30M to a low estimate of $2M. As of the current estimate, Atara Biotherapeutics Inc’s year-ago sales were $221k, an estimated increase of 5,126.20% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for ATRA’s current fiscal year. The highest revenue estimate was $32.3M, while the lowest revenue estimate was $6M, resulting in an average revenue estimate of $15.42M. In the same quarter a year ago, actual revenue was $63.57M, down -75.70% from the average estimate.
